Evidence map›Paper›PMID 40240622›Full record

ArticleNature cancer2025

Author Correction: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial.

Won Seog Kim, Tae Min Kim, Seok-Goo Cho, Isidro Jarque, Elżbieta Iskierka-Jażdżewska, Li Mei Poon, H Miles Prince, Huilai Zhang, Junning Cao, Mingzhi Zhang and 16 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors.

Won Seog KimSungkyunkwan University School of Medicine, Samsung Medical Center Division of Hematology-Oncology, Seoul, South Korea. wskimsmc@gmail.com.ORCID http://orcid.org/0000-0002-5400-0466
Tae Min KimSeoul National University Hospital, Seoul National University Cancer Research Institute, Seoul, South Korea.ORCID http://orcid.org/0000-0001-6145-4426
Seok-Goo ChoSeoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.
Isidro JarqueHematology Department, Hospital Universitari i Politècnic La Fe, Centro de Investigación Biomédica en Red de Cáncer-CIBERONC, Valencia, Spain.
Elżbieta Iskierka-JażdżewskaCopernicus Memorial Hospital, Department of General Hematology, Medical University of Łódź, Łódź, Poland.
Li Mei PoonDepartment of Haematology-Oncology, National University Cancer Institute, National University Hospital, Singapore, Singapore.
H Miles PrinceEpworth HealthCare and University of Melbourne, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0002-0058-2448
Huilai ZhangDepartment of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Junning CaoFudan University Shanghai Cancer Center, Shanghai, China.
Mingzhi ZhangDepartment of Oncology, First Affiliated Hospital, Zhengzhou University, Zhengzhou, China.
Benoît TessoulinHematology Department, Nantes University Hospital, Nantes, France.
Sung Yong OhDong-A University Hospital, Busan, South Korea.
Francesca LimSingapore General Hospital, Singapore, Singapore.
Cecilia CarpioDepartment of Hematology, Vall d'Hebron Institute of Oncology (VHIO), University Hospital Vall d'Hebron, Autonomous University of Barcelona (UAB), Barcelona, Spain.
Tran-Der TanHematology and Medical Oncology, Koo Foundation Sun Yat Sen Cancer Center, Taipei City, Taiwan.
Sabarish AyyappanUniversity of Iowa Hospital and Clinics, Iowa City, IA, USA.
Antonio GutierrezDepartment of Hematology, Hospital Universitario Son Espases, IdISBa, Palma, Spain.
Jingxian CaiRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Melanie UfkinRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Saleem ShariffRegeneron UK, Ltd., Uxbridge, UK.
Jurriaan Brouwer-VisserRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Aafia ChaudhryRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Hesham MohamedRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Srikanth AmbatiRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Jan WalewskiNarodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy, Warszawa, Poland.
ELM-2 Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40240622
PMCPMC12122359

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.